title: Natural Killer cell control ofBRAFV600Emutant melanoma during targeted therapy.
abstract: Pharmacologic inhibition of the mutant BRAFV600Eprotein in advanced BRAFV600Emelanoma results in a high proportion of patients that respond, but few with durable responses. We have recently revealed that Natural Killer (NK) cells play an essential role in theBRAFV600Einhibitor control of melanoma metastases in mice that may be therapeutically exploited to help overcome drug resistance.
authors.affiliation: Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute ; Herston, Queensland, Australia ; Current appointment - Department of Cancer Immunology and AIDS; Dana-Farber Cancer Institute ; Boston, Massachusetts, USA.
authors.forename: Lucas Ferrari
authors.initials: LF
authors.lastname: de Andrade
authors.affiliation: Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute ; Herston, Queensland, Australia.
authors.forename: Shin Foong
authors.initials: SF
authors.lastname: Ngiow
authors.affiliation: Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute ; Herston, Queensland, Australia ; Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1037; Cancer Research Center of Toulouse (CRCT) ; Toulouse, France.
authors.forename: Ludovic
authors.initials: L
authors.lastname: Martinet
authors.affiliation: Immunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute ; Herston, Queensland, Australia ; School of Medicine; University of Queensland ; Herston, Queensland, Australia.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Smyth
keywords: BRAF; NK cells; cancer immunotherapy; metastases; resistance